🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,920 results for “IO” Clear

  1. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Cancer Prevention Pharma (Ireland) Limited

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  2. ABIRATERONE, 177Lu-PNT2002, GALLIUM (68GA) GOZETOTIDE , ENZALUTAMIDE

    Pharma Mar S.A.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  3. AC-203, Vehicle ointment (Placebo of AC-203 Diacerein 1% Ointment, EU)

    Ology Bioservices Ireland LTD

    Generalized Epidermolysis Bullosa Simplex (EBS)

    phase 3 small molecule active

    1 trial

  4. ACICLOVIR VIATRIS 500 mg, poudre pour solution injectable (I.V.), CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.

    phase 3 small molecule active

    1 trial

  5. ACIDE FOLIQUE CCD 5 mg, comprimé, PLACEBO D'ASPIRINE PROTECT, ASPIRINE PROTECT 100 mg, comprimé gastro-résistant, PLACEBO D'ACIDE FOLIQUE

    Pari Pharma GmbH

    Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.

    phase 3 small molecule active

    1 trial

  6. ACTILYSE 50mg placebo, ACTILYSE, poudre et solvant pour solution injectable et perfusion

    Pari Pharma GmbH

    intermediate-high-risk acute pulmonary embolism

    phase 3 small molecule active

    1 trial

  7. ACTILYSE, poudre et solvant pour solution injectable et perfusion, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 10,000 units powder and solvent for solution for injection, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 5 000 units (25 mg) powder for solution for injection

    Tour Hekla

    Acute ischaemic stroke due to basilar artery occlusion.

    phase 3 small molecule active

    1 trial

  8. ACTISOUFRE, solution pour pulvérisation nasale/buccale en flacon pressurisé, Actisoufre Placebo

    Laboratoire HRA Pharma

    rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy

    phase 3 small molecule active

    1 trial

  9. ADI-PEG-20, Troriluzole, AZD1390

    Adaptive Biotechnologies Corp

    Oncology - Glioblastoma (GBM)

    phase 3 small molecule active

    1 trial

  10. ADRENALINE AGUETTANT 1 mg/ml, solution injectable en ampoule

    Novo mesto

    Cardiorespiratory arrest at birth in full-term newborns

    phase 3 small molecule active

    1 trial

  11. ADVATE 500 IU powder and solvent for solution for injection., VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection.

    Takeda Pharmaceuticals International AG

    severe von Willebrand Disease

    phase 3 small molecule active

    1 trial

  12. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 3 small molecule completed

    1 trial

  13. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  14. AG-348

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    2 trials

  15. AG10

    BridgeBio Oncology Therapeutics

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    phase 3 small molecule terminated

    1 trial

  16. AK112 Injection

    Summit Therapeutics

    Non-Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Hungary Kft.

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial

  19. ALN-TTRSC04, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Hereditary transthyretin-mediated amyloidosis with polyneuropathy

    phase 3 small molecule active

    1 trial

  20. ALPELISIB, ALPELISIB, ALPELISIB

    Cancer Prevention Pharma (Ireland) Limited

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  21. ALTUVOCT 2 000 IU powder and solvent for solution for injection, ALTUVOCT 3 000 IU powder and solvent for solution for injection, ALTUVOCT 4 000 IU powder and solvent for solution for injection, ALTUVOCT 250 IU powder and solvent for solution for injection, ALTUVOCT 1 000 IU powder and solvent for solution for injection, ALTUVOCT 500 IU powder and solvent for solution for injection

    Swedish Orphan Biovitrum AB (publ)

    Haemophilia A

    phase 3 small molecule active

    1 trial

  22. ALVAC-HIV vCP1521 + AIDSVAX

    United Therapeutics Europe Ltd

    HIV Infection

    phase 3 mab completed

    1 trial

  23. ALX1-11

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  24. ALX1-11 (drug)

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources